Bile bioavailability and beneficial outcomes of gastric bypass procedures. |
|
Biodisponibilité de la bile et effets bénéfiques des chirurgies bariatriques de type by-pass |
|
Caractérisation et fonctions des macrophages alternatifs humains dans un contexte de maladies cardio-métaboliques |
|
Décodage du role de GPS2 dans le controle transcriptionnel de l'inflammation du tissu adipeux dans l'obésité |
|
Déterminants et impact de l'inflammation postopératoire sur les complications survenant après une chirurgie cardiaque sous circulation extracorporelle |
|
A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation |
|
Effects of F 12511, a potent ACAT inhibitor, on human adrenocortical cells in culture |
|
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes |
|
EMBO workshop on immunology and metabolism |
|
Endoplasmic reticulum stress actively suppresses hepatic molecular identity in damaged liver |
|
Entrainment of the mammalian circadian clock by metabolism in the liver : a quantitative mathematical model |
|
Erratum: Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes |
|
Etude du récepteur nucléaire peroxisome proliferator-activated receptor alpha (PPARα) in vivo par recombinaison homologue : création et caractérisation de souris humanisées pour PPARα, création de souris porteuses de l'inactivation conditionnelle de PPARα |
|
Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease |
|
Farnesoid X receptor: a new player in glucose metabolism? |
|
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression |
|
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity |
|
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells |
|
Fasting the Microbiota to Improve Metabolism? |
|
Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells |
|
Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein |
|
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease |
|
Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. |
|
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation |
|
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates |
|
Fibrates in CVD: a step towards personalised medicine |
|
Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat |
|
Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression |
|
Fluid retention mediated by renal PPARgamma |
|
Free leptin, carotid plaque phenotype and relevance to related symptomatology: insights from the OPAL-Lille carotid endarterectomy study |
|
From cardiac mitochondrial dysfunction to clinical arrhythmias |
|
A fully dissociated compound of plant origin for inflammatory gene repression |
|
Function of the transcriptional regulating protein of 132 kDa (TReP-132) on human P450scc gene expression |
|
Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs? |
|
FXR-deficiency confers increased susceptibility to torpor. |
|
FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity |
|
General molecular biology and architecture of nuclear receptors |
|
Generation and characterization of a humanized PPARδ mouse model |
|
Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders |
|
Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor α in mouse liver reveals extensive sharing of binding sites |
|
Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes |
|
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes |
|
Giardia muris infection in mice is associated with a protective interleukin 17A response and induction of peroxisome proliferator-activated receptor alpha |
|
Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate |
|
Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization |
|
Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). |
|
Hepatoprotective effects of PPARα : molecular basis and pathophysiological role of PPARα in acute inflammation and non-alcoholic steatohepatitis. |
|
Impact of FAT10 overexpression during NASH progression on PPARα expression and activity. |
|
Impact of Insulin-Degrading Enzyme modulation on liver Unfolded Protein Response. |
|
Impact of macrophage glutaminolysis on cardio-metabolic diseases. |
|
Impact of nonalcoholic steatohepatitis on myocardial remodeling and cardiovascular complications. |
|
Modélisation mathématique du couplage entre horloge circadienne et métabolisme dans le foie. |
|
An oxidative stress paradox: time for a conceptual change? |
|
Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages |
|
Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism |
|
A Post-Hoc Analysis ofthe Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy |
|
Le récepteur nucléaire FXR : identification de nouveaux gènes cibles impliqués dans le contrôle du métabolisme lipidique et étude de l'effet de la phosphorylation sur son activité |
|
Régulation épigénétique de la lipolyse intravasculaire des triglycérides |
|
Rôle de FAT10 dans la sénescence des hépatocytes et le développement de la NASH |
|
Rôle de la signalisation LRP1/Wnt5a dans le métabolisme du cholestérol |
|
Role de récepteur nucléaire ROR-alpha dans les lymphocytes T régulateurs. |
|
Rôle de Wnt5a dans le trafic intracellulaire du cholestérol et l'athérosclérose |
|
Rôle des acides biliaires dans la physiopathologie de l'obésité, la résistance à l'insuline, le diabète de type 2, la stéatose hépatique non alcoolique et dans le contexte de la chirurgie bariatrique |
|
Rôle des récepteurs nucléaires PPARα et Rev-erbα dans le métabolisme des lipides et lipoprotéines, et le développement de l'athérosclérose |
|
Rôle du facteur de transcription TReP-132 dans la prolifération et la différenciation des cellules de cancers mammaires |
|
Rôle du récepteur nucléaire farnesoid X receptor (FXR) dans le métabolisme glucidique : une fonction potentielle dans le diabète de type 2 et dans l'adaptation métabolique du foie |
|
Rôle et régulation du récepteur nucléaire orphelin REV-ERB α : voies d'interaction avec les récepteurs nucléaires PPARγ et LXR |
|
Rôle of the Farnesoid X receptor in the central control of energy homeostasis. |
|
The role of the nuclear receptor Rev-erb-alpha in inflammatory diseases : the circadian regulation of the NLRP3 inflammasome complex in fulminant hepatitis and the repression of the development of atherosclerosis and vascular calcification. |
|
en scientific article |
|
Signalisation par le récepteur des acides biliaires TGR5 et modulation de la barrière épithéliale biliaire |
|
Thyroid hormones and metabolic disorders. |
|
What changes in intestinal functions occurs when obesity is complicated by metabolic diseases? : some elements of answer by the study of the intestinal transcriptome of severely obese patients of the ABOS cohort. |
|